Publication of an interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children of 12 years and older)

The scientific opinion given for remdesivir via the Early Access to Medicines Scheme has now lapsed, and an interim clinical commissioning policy has been put in place to define routine access to the drug in the treatment of COVID-19 across the UK.


Medicines and Healthcare products Regulatory Agency